Iradimed Corporation (NASDAQ:IRMD) Short Interest Up 16.5% in February

Iradimed Corporation (NASDAQ:IRMD - Get Free Report) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 201,000 shares, an increase of 16.5% from the February 13th total of 172,600 shares. Approximately 2.5% of the company's stock are sold short. Based on an average trading volume of 42,800 shares, the short-interest ratio is currently 4.7 days.

Analysts Set New Price Targets

IRMD has been the subject of several recent research reports. Roth Mkm reissued a "buy" rating and set a $72.00 target price (up from $60.00) on shares of Iradimed in a research report on Friday, February 14th. StockNews.com downgraded shares of Iradimed from a "strong-buy" rating to a "buy" rating in a research report on Thursday, March 13th.

Institutional Investors Weigh In On Iradimed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Iradimed during the 4th quarter valued at approximately $30,000. US Bancorp DE grew its position in shares of Iradimed by 476.6% during the 4th quarter. US Bancorp DE now owns 617 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 510 shares during the period. Huntington National Bank grew its position in shares of Iradimed by 51.3% during the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider's stock valued at $75,000 after acquiring an additional 504 shares during the period. Quantbot Technologies LP grew its position in shares of Iradimed by 83.0% during the 3rd quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider's stock valued at $117,000 after acquiring an additional 1,052 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Iradimed during the 3rd quarter valued at approximately $126,000. Hedge funds and other institutional investors own 92.34% of the company's stock.

Remove Ads

Iradimed Stock Performance

NASDAQ:IRMD traded down $0.17 on Friday, hitting $52.33. The stock had a trading volume of 64,343 shares, compared to its average volume of 43,453. The stock has a market cap of $665.38 million, a P/E ratio of 34.89 and a beta of 0.83. Iradimed has a 1 year low of $40.18 and a 1 year high of $63.29. The firm's fifty day simple moving average is $56.60 and its two-hundred day simple moving average is $53.63.

Iradimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.05). The firm had revenue of $19.39 million during the quarter, compared to analysts' expectations of $19.09 million. Iradimed had a net margin of 26.26% and a return on equity of 24.12%. Equities research analysts predict that Iradimed will post 1.66 EPS for the current year.

Iradimed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 5th. Shareholders of record on Monday, February 24th were paid a $0.17 dividend. This is a positive change from Iradimed's previous quarterly dividend of $0.15. The ex-dividend date was Monday, February 24th. This represents a $0.68 annualized dividend and a yield of 1.30%. Iradimed's dividend payout ratio (DPR) is 45.33%.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.